Close Menu
Home » Cynvenio, ATGen Initiate Pilot Study of Combo Cancer Test

Cynvenio, ATGen Initiate Pilot Study of Combo Cancer Test

Dec 28, 2015
|
staff reporter

NEW YORK (GenomeWeb) – Cynvenio Biosystems announced today that it has launched a pilot surveillance study with South Korea's ATGen Global to evaluate a new method for the early detection of cancer recurrence in triple-negative breast cancer patients. Cynvenio's ClearID test will be combined with ATGen's NK Vue blood test to detect cancer recurrence in women who have previously been treated for triple-negative breast cancer and show no radiographic signs of metastases.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Coronavirus Case Reported in US

The Los Angeles Times reports that a case of the novel coronavirus making people ill in China has been reported in the US. 

Increase Sought for 'Industries of the Future'

A bipartisan group of senators has introduced a bill seeking increased funding for certain fields, including synthetic biology, ScienceInsider reports. 

Ring Materials

Discover magazine writes that paleoproteomics is increasing being used in archaeology, paleoanthropology, and paleontology, including a recent study of a 6,000-year-old ring. 

Nucleic Acids Research Papers Look at Light Mutagenesis, Synonymous Variants With Post-Transcriptional Effects, More

In Nucleic Acids Research this week: mutagenic effects of ultraviolet "A" light, post-transcription effects of synonymous mutations, and more.

What's Popular?

In Business News

  1. Quest Diagnostics Acquires Blueprint Genetics

  2. 10x Genomics Lawsuit Over Exclusivity of Harvard Single-Cell IP License Going to Trial

  3. Illumina Targets Single-Cell, Oncology Applications With New NextSeq Platform

    Premium

  4. Adaptive Biotechnologies Announces Preliminary FY19 Revenue Increase, $257M Stock Offering

  5. Abbott Q4 Diagnostics Revenues up 5 Percent, MDx Revenues Decline

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.